Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes

Virology

Volumn 364, Issue 2, 2007, Pages 431-440

  Ketas, Thomas J ^a   Schader, Susan M ^a   Zurita, Juan ^a   Teo, Esther ^a   Polonis, Victoria ^b   Lu, Min ^a   Klasse, Per Johan ^a   Moore, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Clades; Entry inhibitors; HIV 1; Microbicide; R5 X4 tropism

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; AMD 3465; C52L; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CMPD 167; MICROBICIDE; UNCLASSIFIED DRUG;

ARTICLE; DRUG BLOOD LEVEL; GENETIC ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LYMPHOCYTE CULTURE; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE; VIRUS ISOLATION; VIRUS REPLICATION;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; PIPERAZINES; PYRAZOLES; PYRIDINES; RECEPTORS, CCR5; RECEPTORS, CXCR4; SEXUAL BEHAVIOR; VALINE; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34147186687     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.03.001     Document Type: Article

References (46)

1. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 23 (2004) 13232-13252
2. Brown B.K., Darden J.M., Tovanabutra S., Oblander T., Frost J., Sanders-Buell E., de Souza M.S., Birx D.L., McCutchan F.E., and Polonis V.R. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J. Virol. 79 10 (2005) 6089-6101
3. Brumme Z.L., Goodrich J., Mayer H.B., Brumme C.J., Henrick B.M., Wynhoven B., Asselin J.J., Cheung P.K., Hogg R.S., Montaner J.S., and Harrigan P.R. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J. Infect. Dis. 192 3 (2005) 466-474
4. Burton D.R., Williamson R.A., and Parren P.W. Antibody and virus: binding and neutralization. Virology 270 1 (2000) 1-3
5. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., and Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 3 (2004) 233-236
6. Cilliers T., Nhlapo J., Coetzer M., Orlovic D., Ketas T., Olson W.C., Moore J.P., Trkola A., and Morris L. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J. Virol. 77 7 (2003) 4449-4456
7. Deng Y., Zheng Q., Ketas T.A., Moore J.P., and Lu M. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry (2007) [Electronic publication ahead of print]
8. Dhawan D., and Mayer K.H. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. J. Infect. Dis. 193 1 (2006) 36-44
9. Gallo S.A., Finnegan C.M., Viard M., Raviv Y., Dimitrov A., Rawat S.S., Puri A., Durell S., and Blumenthal R. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614 1 (2003) 36-50
10. Guo Q., Ho H.T., Dicker I., Fan L., Zhou N., Friborg J., Wang T., McAuliffe B.V., Wang H.G., Rose R.E., Fang H., Scarnati H.T., Langley D.R., Meanwell N.A., Abraham R., Colonno R.J., and Lin P.F. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 77 19 (2003) 10528-10536
11. Gupta K., and Klasse P.J. How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked?. PLoS Med. 3 2 (2006) e79 181-185
12. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev., Immunol. 5 10 (2005) 783-792
13. Hatse S., Princen K., De Clercq E., Rosenkilde M.M., Schwartz T.W., Hernandez-Abad P.E., Skerlj R.T., Bridger G.J., and Schols D. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem. Pharmacol. 70 5 (2005) 752-761
14. Hladik F., Sakchalathorn P., Ballweber L., Lentz G., Fialkow M., Eschenbach D., and McElrath M.J. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26 2 (2007) 257-270
15. Ketas T.J., Frank I., Klasse P.J., Sullivan B.M., Gardner J.P., Spenlehauer C., Nesin M., Olson W.C., Moore J.P., and Pope M. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J. Virol. 77 4 (2003) 2762-2767
16. Ketas T.J., Klasse P.J., Spenlehauer C., Nesin M., Frank I., Pope M., Strizki J.M., Reyes G.R., Baroudy B.M., and Moore J.P. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res. Hum. Retroviruses 19 3 (2003) 177-186
17. Klasse P.J., and Sattentau Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83 9 (2002) 2091-2108
18. Klasse P.J., Shattock R.J., and Moore J.P. Which topical microbicides for blocking HIV-1 transmission will work in the real world?. PLoS Med. 3 9 (2006) 1501-1507
19. Lederman M.M., Offord R.E., and Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Immunol. Rev. 6 5 (2006) 371-382
20. Lee M.T., Coburn G.A., McClure M.O., and Cullen B.R. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J. Virol. 77 22 (2003) 11964-11972
21. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 16 (2005) 10108-10125
22. Lu H., Zhao Q., Wallace G., Liu S., He Y., Shattock R., Neurath A.R., and Jiang B.S. Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 22 5 (2006) 411-418
23. Margolis L., and Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?. Nat. Rev., Microbiol. 4 4 (2006) 312-317
24. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., and Montefiori D.C. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79 16 (2005) 10103-10107
25. Matthews T., Salgo M., Greenberg M., Chung J., DeMasi R., and Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev., Drug Discov. 3 3 (2004) 215-225
26. McCutchan F.E. Global epidemiology of HIV. J. Med. Virol. 78 Suppl. 1 (2006) S7-S12
27. Miller C.J., Li Q., Abel K., Kim E.Y., Ma Z.M., Wietgrefe S., La Franco-Scheuch L., Compton L., Duan L., Shore M.D., Zupancic M., Busch M., Carlis J., Wolinsky S., and Haase A.T. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 79 14 (2005) 9217-9227
28. Moore J.P., and Burton D.R. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat. Med. 10 8 (2004) 769-771
29. Moore J.P., Kitchen S.G., Pugach P., and Zack J.A. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 20 1 (2004) 111-126
30. Moyle G.J., Wildfire A., Mandalia S., Mayer H., Goodrich J., Whitcomb J., and Gazzard B.G. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. 191 6 (2005) 866-872
31. Olson W.C., and Maddon P.J. Resistance to HIV-1 entry inhibitors. Curr. Drug Targets, Infect. Disord. 3 4 (2003) 283-294
32. Pope M., Frankel S.S., Mascola J.R., Trkola A., Isdell F., Birx D.L., Burke D.S., Ho D.D., and Moore J.P. Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism. J. Virol. 71 10 (1997) 8001-8007
33. Rusert P., Kuster H., Joos B., Misselwitz B., Gujer C., Leemann C., Fischer M., Stiegler G., Katinger H., Olson W.C., Weber R., Aceto L., Gunthard H.F., and Trkola A. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J. Virol. 79 13 (2005) 8454-8469
34. Shattock R.J., and Moore J.P. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev., Microbiol. 1 1 (2003) 25-34
35. Tremblay C.L., Giguel F., Kollmann C., Guan Y., Chou T.C., Baroudy B.M., and Hirsch M.S. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. 46 5 (2002) 1336-1339
36. Tremblay C.L., Giguel F., Chou T.C., Dong H., Takashima K., and Hirsch M.S. TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro. Antiviral Ther. 10 8 (2005) 967-968
37. Tremblay C.L., Giguel F., Guan Y., Chou T.C., Takashima K., and Hirsch M.S. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro. Antimicrob. Agents Chemother. 49 8 (2005) 3483-3485
38. Trkola A., Ketas T., Kewalramani V.N., Endorf F., Binley J.M., Katinger H., Robinson J., Littman D.R., and Moore J.P. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72 3 (1998) 1876-1885
39. Trkola A., Ketas T.J., Nagashima K.A., Zhao L., Cilliers T., Morris L., Moore J.P., Maddon P.J., and Olson W.C. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75 2 (2001) 579-588
40. Veazey R.S., Klasse P.J., Schader S.M., Hu Q., Ketas T.J., Lu M., Marx P.A., Dufour J., Colonno R.J., Shattock R.J., Springer M.S., and Moore J.P. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438 7064 (2005) 99-102
41. Walker B.D., and Korber B.T. Immune control of HIV: the obstacles of HLA and viral diversity. Nat. Immunol. 2 6 (2001) 473-475
42. Willey S., Peters P.J., Sullivan W.M., Dorr P., Perros M., and Clapham P.R. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. Antiviral Res. 68 2 (2005) 96-108
43. Yeni P.G., Hammer S.M., Hirsch M.S., Saag M.S., Schechter M., Carpenter C.C., Fischl M.A., Gatell J.M., Gazzard B.G., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Schooley R.T., Thompson M.A., Vella S., and Volberding P.A. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292 2 (2004) 251-265
44. Yi Y., Shaheen F., and Collman R.G. Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes. J. Virol. 79 3 (2005) 1480-1486
45. Zhang Y.J., and Moore J.P. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?. J. Virol. 73 4 (1999) 3443-3448
46. Zhang Y.J., Dragic T., Cao Y., Kostrikis L., Kwon D.S., Littman D.R., KewalRamani V.N., and Moore J.P. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J. Virol. 72 11 (1998) 9337-9344